

1 *Early trends for SARS-CoV-2 infection in central and north Texas and impact on other circulating*
2 *respiratory viruses*

3 **Manohar B. Mutnal¹, Alejandro C. Arroliga³, Kimberly Walker¹, Amin Mohammad¹, Matthew M.**
4 **Brigmon², Ryan M. Beaver², John K. Midturi² and Arundhati Rao¹**

5 Author affiliation:

- 6 1. Department of Pathology and Laboratory Medicine, Baylor Scott & White Medical Center, 2401
7 South 31st Street, Temple, TX 76508
8 2. Department of Infectious Diseases, Baylor Scott & White Medical Center, 2401 South 31st Street,
9 Temple, TX 76508
10 3. Department of Pulmonary Medicine and Critical Care and Chief Medical Officer, Baylor Scott &
11 White Medical Center, 2401 South 31st Street, Temple, TX 76508

12
13 *Address for correspondence*

14 *Manohar B. Mutnal, Ph.D.*

15 *Section Chief – Microbiology*

16 *Department of Pathology and Laboratory Medicine*

17 *2401, South 31st street, Temple TX 76508*

18 *Manohar.mutnal@bswhealth.org*

19 *Phone: 254-724-2714*

20 *Short title: COVID-19 testing in Central and North Texas, USA*

21

22

23 **Abstract:**

24 **Introduction:** Rapid diagnosis and isolation are key to containing the quick spread of a pandemic agent
25 like *SARS-CoV-2*, which has spread globally since its initial outbreak in Wuhan province in China. *SARS-*
26 *CoV-2* is novel to most parts of the world including USA and the effect on typically prevalent seasonal
27 viruses is just becoming apparent. We present our initial data on the prevalence of respiratory viruses in
28 the month of March, 2020.

29 **Methods:** This is a retrospective cohort study post launching of *SARS-CoV-2* testing at Baylor Scott and
30 White Hospital (BSWH), Temple TX. Testing for *SARS-CoV-2* was performed by real-time rRT-PCR
31 assay and results were shared with State public health officials for immediate interventions.

32 **Results:** More than 3500 tests were performed during the first two weeks of testing for *SARS-CoV-2* and
33 identified 168 (4.7%) positive patients. Sixty-two (3.2%) of the 1,912 ambulatory patients and 106 (6.3%)
34 of the 1,659 ED/inpatients were tested positive. Higher rate of infection (6.9%) were noted in the patients
35 belonging to age group 25-34 years and least number of positive cases were noted in <25 years old (2%)
36 group. The TX State county specific patient demographic information was shared with respective public
37 health departments for epidemiological interventions.

38 Incidentally, this study showed that there was a significant decrease in the occurrence of infections due to
39 seasonal respiratory viruses in this region, perhaps due to increased epidemiological awareness, about
40 *SARS-CoV-2*, among general public. Data extracted for BSWH from the CDC's National Respiratory and
41 Enteric Virus Surveillance System (NREVSS) site revealed that Influenza incidence declined to 8.7% in
42 March 2020 compared to 25% in March 2019.

43 **Conclusions:** This study was intended to provide an initial experience of dealing with a pandemic and the
44 role of laboratories in crisis management. This study provided *SARS-CoV-2* testing data from ambulatory
45 and inpatient population. Epidemiological interventions depend on timely availability of accurate
46 diagnostic tests and throughput capacity of such systems during large outbreaks like *SARS-CoV-2*.

47 **Key words: COVID-19, SARS-COV-2, rRT-PCR, diagnosis, Epidemiology**

48

49 **Introduction:**

50 In December 2019, Wuhan city, the capital of Hubei province in China, became the center of an
51 outbreak of pneumonia of unknown cause. By Jan 7, 2020, Chinese scientists had isolated a novel
52 coronavirus, severe acute respiratory syndrome coronavirus 2 (*SARS-CoV-2*; previously known as 2019-
53 nCoV), from these patients with virus-infected pneumonia.¹ Cases have now spread to 190 countries. As
54 of March 23, 2020 there were more than 372,000+ confirmed cases and 16,000+ deaths.² Although the
55 outbreak is likely to have started from a zoonotic transmission event associated with a large seafood
56 market that also traded in live wild animals, it soon became clear that efficient person-to-person
57 transmission was also occurring.³

58 The clinical spectrum of *SARS-CoV-2* infection appears to be wide, encompassing asymptomatic
59 infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure and
60 even death, with many patients being hospitalized with pneumonia in Wuhan and elsewhere.⁴ A global
61 pandemic has erupted due to a high proportion of asymptomatic patients coupled with a high degree of
62 viral shedding, long incubation period, and late clinical manifestations. Prolific testing, therefore,
63 remains one of the most effective epidemiological interventions to stop early community spread.
64 Unfortunately, the novelty of *SARS-CoV-2* meant that no testing was immediately available making it
65 difficult for public health officials to stay ahead of the pandemic curve.

66
67 As State Public health laboratories became backlogged, Baylor Scott and White hospital system
68 (BSWH) collaborated with the Luminex Corporation (Austin, TX USA) to implement a *SARS-CoV-2*
69 real-time reverse transcription polymerase chain reaction (rRT-PCR) assay using the genetic primers
70 previously used in China to help relieve the bottleneck. BSWH laboratory was one of the first laboratories
71 in Texas State to adopt *SARS-CoV-2* testing to assist state public health officials for tracing and tracking
72 patients and their immediate contacts. As the pandemic continues to spread across the nation, goal of this
73 study was to share the early clinical trends for COVID-19 in north and central regions of Texas. The aim

74 of this study is to encourage other laboratories to consider an early start to testing during pandemics, share
75 initial trends in this part of the world and possible impact of *SARS-CoV-2* on other seasonal respiratory
76 viruses. This report describes the early trends of *SARS-CoV-2* infections in the central and north Texas,
77 USA and impact of epidemiological interventions that may have led to the decrease in the incidence of
78 seasonal respiratory virus infections

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103 **Methods:**

104 This study was reviewed and approved by the Baylor Scott and White Health Institutional Review board
105 (IRB # 344003)

106 *Study design and participants:*

107 This retrospective cohort study included two cohorts of adult inpatients from Baylor Scott &
108 White Medical Center in Temple (Temple, TX), representing the central Texas region, and various Baylor
109 hospitals in Dallas, TX area, representing north Texas region. For the simplicity, all hospitals within
110 Baylor organization will be referred to as BSW hospitals (BSWH). All adult patients were prescreened
111 according to WHO and BSWH guidelines to be eligible for *SARS-CoV-2* testing. Briefly, patients were
112 prescreened on BSWH web portal, phone app and/or through e-visit prior to making appointment for
113 specimen collection at one of the several designated locations. Patients were asked for travel history and
114 any other associated symptoms such as fever, cough and shortness of breath. When clinically indicated,
115 *SARS-CoV-2* testing was ordered by the attending physician or by other care providers.

116 As BSWH laboratory continues testing, this study included data from the day testing began on
117 March 11, 2020 and until March 23, 2020. These two hospital systems within BSWH represent central
118 and north Texas population and are limited to these regions of Texas due to community outreach. Study
119 includes data for *SARS-CoV-2* testing from these two regions and seasonal respiratory virus testing data is
120 limited to central Texas region.

121 *Data collection*

122 Epidemiological, demographic, clinical and laboratory data were extracted from electronic
123 medical records and laboratory information system.

124 **Laboratory procedures**

125 *SARS-CoV-2* testing

126 Methods for laboratory confirmation of *SARS-CoV-2* infection were based on rRT-PCR technique
127 approved by FDA (US Federal Drug and Food Administration) under Emergency Use Authorization
128 (EUA)⁵. Briefly, all BSWH nasopharyngeal specimens were collected either by drive through collection
129 sites or from inpatients using a flocked swab in Universal or Transport Media (Copan Technologies,
130 USA). Specimens were transported at 2 - 8 °C to BSWH (Temple, TX) molecular pathology laboratory
131 for processing and testing with less than 3 hours of transit time. BSWH (Temple, TX) molecular
132 pathology laboratory was responsible for *SARS-CoV-2* detection in respiratory specimens by real-time
133 reverse transcription polymerase chain reaction (rRT-PCR) methods (Luminex Corporation, Austin, TX
134 USA).

135 The *SARS-CoV-2* primers were designed by manufacturer of the assay to detect RNA targets from
136 the *SARS-CoV-2* in respiratory specimens from patients as recommended for testing by public health
137 authority guidelines. The method employs two primers for amplifying *ORF1* gene and *N* gene from
138 *SARS-CoV-2* virus and the assay includes extraction and internal controls built in the same cartridge.
139 Internal sample processing controls to verify sample lysis, nucleic acid extraction, and proper system and
140 reagent performance are built into each Luminex Extraction Cartridge. Human RNAase P was used as an
141 internal control. Luminex Aries offers true random-access testing, however, increased demand for testing
142 necessitated validation of a similar assay on the Luminex NxTAG platform for batched testing, this
143 method includes additional *Envelope (E)* gene target for *SARS-CoV-2* detection. The Luminex NxTAG
144 platform offers high throughput but on a batched processing using similar primers as Luminex Aries.
145 Both assays had received FDA Emergency Use Authorization prior to submission of this manuscript.

146 *Other respiratory virus testing*

147 BSWH utilizes respiratory virus syndromic panel, also from Luminex, for the diagnosis of upper
148 respiratory infections. This Luminex NxTAG assay was used as previously described⁶. The assay detects
149 *Influenza A and B, Respiratory Syncytial Virus (RSV), Parainfluenza 1-4, Human metapneumovirus,*
150 *Rhinovirus/Enterovirus, Adenovirus, Bocavirus, Coronaviruses HKU1, NL63, 229E, OC43,*

151 *Chlamydomydia pneumoniae*, *Legionella pneumophila* and *Mycoplasma pneumoniae*. DNA/RNA is
152 extracted using an automated extraction. This test is based on Luminex's respiratory pathogen panel
153 technology to amplify multiple targets within a single tube and is read on the Luminex MagPix
154 workstation. In addition, BSWH laboratory uses standalone PCR tests for *Influenza* and *RSV* on Roche
155 LIAT system (Roche molecular, Indianapolis, IN USA) or Luminex Aries and the tests performed on
156 these instruments were included in the data analysis for this study. A *Chi*-square test was used to assess
157 the association between the rate of infection for each virus between 2019 and 2020. Statistical
158 significance was set at $p\text{-value} < 0.05$.

159

160

161

162

163

164

165

166

167

168

169

170

171

172 **Results**

173 *BSWH testing burden during initial periods of community spread*

174 BSWH laboratory was one of the first few laboratories in the Texas State to start testing for
175 *SARS-CoV-2* using Luminex Aries system. The assay was developed and validated for FDA approval
176 under the Emergency Use Authorization on March 10th, 2020. While BSWH EUA application was under
177 review by FDA manufacturer received FDA EUA on April 03, 2020 before this manuscript was submitted
178 hence BSWH laboratory accepted manufacturer's performance claims with limited internal verification.
179 The BSWH laboratory started patient testing on March 11, 2020 and supported all the Baylor hospitals in
180 central and north Texas regions. Data presented in figure 1 includes daily test volumes, combined from
181 both Luminex Aries and NxTAG platforms. A total of 3,571 nasopharyngeal specimens were tested until
182 March 23rd, 2020. The north Texas region contributed 1,219 while central Texas region 2,352 specimens.
183 The typical turnaround time for specimen collection to verification of test results was less than 15 hours.

184 *SARS-CoV-2 positive cases and age distribution*

185 Individuals were delivered a prescreening questionnaire to be eligible for testing through BSWH
186 web portal, phone app and/or through e-visit. The questionnaire focused on current symptoms, travel and
187 other exposure history. Eligible patients were directed to visit one of the drive through collection sites
188 established ad hoc for collection of nasopharyngeal specimen.

189 Patients with specific symptoms visiting emergency department were tested for *SARS-CoV-2* and
190 were either discharged while waiting for test results for self-quarantine at home or admitted if clinical
191 findings necessitated. Clinical symptoms and underlying morbidities for limited number of ED/inpatients
192 are presented in Table 1. More than 75% of the patients presented in emergency department had fever and
193 cough.

194 A total of 3,571 *SARS-CoV-2* rRT-PCR tests were performed at BSWH laboratory, 1,912
195 specimens were received from ambulatory and/or drive-through collection sites, and 1,659 from the

196 ED/inpatient. Sixty-two (3.2%) ambulatory patients were tested positive, as did 106 (6.3%) ED/inpatient
197 population, noted in Figures 4 and 5, respectively.

198 BSWH initial trends indicated a marked increase in the number of positive cases in the 25 years
199 to 34 years age group (7.4%) followed by 6.9% in 55 years to 64 years age group. Data presented here
200 indicated a lower incidence (2%) among the <25 years old (Figure 4).

201 *Number of confirmed cases per specific county in north and central Texas, USA*

202 An appropriate epidemiological intervention requires identification of patient demographics for
203 public health officials to track and trace positive cases. Therefore, it is prudent that *SARS-CoV-2* testing
204 laboratories work closely with local epidemiologists for effective communication of test results. BSWH
205 had previously built an electronic bridge with Texas Department of State Health Services for instant
206 communication of all notifiable conditions. *SARS-CoV-2* results were added to this electronic health
207 reporting system for an efficient communication to state epidemiologists.

208 Major metro areas, both in central and north Texas, witnessed an increased number of positive
209 cases. Dallas county (north Texas) and Travis county (central Texas) had maximum number of positive
210 cases while this manuscript was under preparation (Figure 5).

211 *COVID-19 impact on other circulating respiratory viruses*

212 As local, state, and national epidemiologic countermeasures were enacted, this study observed an
213 interesting correlation between *SARS-CoV-2* positive cases and the incidence of other seasonal circulating
214 respiratory viruses during the same timeframe. Data extracted for BSWH from the CDC's National
215 Respiratory and Enteric Virus Surveillance System (NREVSS) site revealed that Influenza incidence
216 declined to 8.7% in March 2020 compared to 25% in March 2019 ($p < 0.0001$). This declining trend over
217 the last few weeks coincides with sharp uptick in the *SARS-CoV-2* incidence. This study also observed
218 that *Bocavirus* and *Parainfluenza* virus infections were significantly down in March, 2020 compared to
219 March, 2019 ($p < 0.05$). Authors did not note a similar decline in *Adenovirus*, common cold *Coronavirus*,

220 *Human Metapneumovirus, Rhinovirus and RSV* infections for March, 2020 compared to March, 2019
221 (Figure 6).

222 This study also looked at co-infections rates from *SARS-CoV-2* positive patients. We searched for
223 262 patient records that had concurrent testing requests for *SARS-CoV-2* and other respiratory virus
224 infections. Contrary to several other reports from other parts of the nation, this study did not notice any
225 co-infection cases with *SARS-CoV-2*.

226

227 **Discussion**

228 The *SARS-CoV-2* literature is evolving at breakneck pace, but there is a paucity of literature
229 detailing in-house testing solutions to combat the national delays in turn-around time or the shortages of
230 testing kits available. As real-time rRT-PCR is already widely deployed in diagnostic virology
231 laboratories, this study recommends any institution with molecular testing capabilities consider
232 proactively reaching out to manufacturers to improve testing capabilities and turn-around time. In the race
233 against this pandemic, real-time data empower epidemiologists and public health officials to identify,
234 track, and contain spread as much as possible. Integrating laboratory-based reporting with epidemiologic
235 surveillance registers will only further improve public health outcomes.

236 The intent of this study was not to assess the performance characters of the rRT-PCR assay for
237 the detection of *SARS-CoV-2* infection. Authors are of the opinion that accurate determination of test
238 performance characters will require appropriate distribution of cohorts among the general population
239 especially in the context of virus shedding, transmission dynamics, asymptomatic carriage and specimen
240 requirements are still being debated and investigated. *SARS-CoV-2* has exhibited great degree of plasticity
241 in all of the above characters hence it may take additional time and understanding to determine the
242 performance characters of the assay.

243 The literature data available at the time of the emergency were few for most USA healthcare
244 systems and above all stemming from the only experience available on the outbreak from COVID 2019.
245 The only country with published data and epidemiological or management studies was represented by the
246 Chinese outbreak.⁷ However, the health system and the Chinese government represent a very different
247 model from the USA reality where healthcare is regional and private for most part, which enjoys
248 significant autonomy such as the possibilities available to try to improve and optimize diagnosis,
249 management and partnership with public health officials. In this context, BSWH ramped up efforts in
250 laboratory diagnosis and collegial collaboration with public health officials for effective epidemiological
251 interventions.

252 Because *SARS-CoV-2* infection symptoms range from unspecific mild respiratory symptoms to
253 acute respiratory distress⁴ and because these symptoms are very similar to those of many seasonal
254 viruses,⁸ BSWH laboratory implemented an outpatient screening protocols hosted on BSWH web portal
255 for appointments, phone app and e-visit sites for appropriate prescreening of individuals for targeted
256 laboratory testing.

257 Real-time rRT-PCR testing for various other infections is widely deployed in most diagnostic
258 laboratories. In the case of a public health emergency, proficient diagnostic laboratories can rely on this
259 robust technology to establish new diagnostic tests within their routine services before pre-formulated
260 assays become available. In addition to information on reagents, oligonucleotides and positive controls,
261 laboratories working under quality control programs need to rely on documentation of technical
262 qualification of the assay formulation as well as data from external clinical evaluation tests.^{8,9} Everything
263 listed above can be true for a laboratory-developed test, however, if commercial manufacturers design
264 assays under FDA watch then all of the above requirements can be mitigated. The available genome
265 sequence of *SARS-CoV-2* has enabled several diagnostic kit manufacturers to design their primer sets for
266 real-time rRT-PCR diagnostic test builds¹¹ in addition to other respiratory pathogens testing.

267 BSWH worked diligently with Luminex Corporation to adopt and submit an FDA emergency use
268 authorization application of their assay for BSWH healthcare system during early phases of community
269 spread in Texas State. This early adoption of rRT-PCR assay led to improved turnaround times of *SARS-*
270 *CoV-2* test results, reduced testing burden of public health laboratory, and won praise from the local
271 public health officials for efficient communication of test results for appropriate interventions.

272 To best of authors' knowledge, this is the first report on *SARS-CoV-2* testing from this part of the
273 world. BSWH laboratory would like to share this information with our readers and other laboratories that
274 early adoption of testing for pandemic diseases like COVID-19 has long-term implications in management
275 and control measures. BSWH laboratory provided test results data on both ambulatory and inpatient
276 population, and shared patient demographics with local public health officials.

277 This study provided limited insights into clinical manifestations of patient who either reported to
278 emergency department or admitted for further evaluations. Major symptoms included were fever and
279 cough, more than 75% of the patients reported to have these symptoms. Khuwara *et al*¹² reported similar
280 findings in Wuhan outbreak, reporting greater than 90% and 75% of the patients exhibiting fever and
281 cough, respectively.

282 Interestingly, data mining did not yield any co-infections with *SARS-CoV-2* unlike Stanford
283 Medicine data¹³. This study attributes the initial trend of not finding co-infections with *SARS-CoV-2* to
284 limited concurrent test ordering for other respiratory viruses in an ambulatory setting. A generic notion of
285 prohibitive cost of respiratory syndromic panels may have led to the limited ordering in outpatient testing.

286 The coronavirus disease 2019 has rapidly spread around the world, posing enormous health,
287 economic, and social challenges to societies. As there are no proven drug and vaccine treatments,¹⁴ non-
288 pharmaceutical measures are essential to slow the spread of the epidemic.¹⁵ Social distancing (e.g.,
289 cancellation of large gathering, school closures) is an essential part of public health measure for infection
290 control.¹⁵ In line with this, many social events and activities have been cancelled or scaled-down in many
291 countries including Japan,² wherein there is already a high number of reported COVID-19 cases.

292 This study demonstrated an incidental correlation of decline in the other respiratory viruses such
293 as *Influenza* viruses typically circulating during this time of the year. This observation may be merely
294 coincidental, however, this study hypothesized that the general epidemiological measures such as social
295 distancing, cancellation of large gatherings and in general population is being extra-careful in preventing
296 *SARS-CoV-2* infection may have led to the decrease in *Influenza* cases compared to what BSWH
297 laboratory witnessed last year around the same period of time. This study must not be intended to draw
298 any definitive conclusion on this fact, especially when data for 2019-2020 flu vaccine effectiveness is still
299 evolving.

300

301 **Conclusion**

302 This study was intended to provide an initial experience of dealing with a pandemic and how
303 laboratories are required to be part of the crisis management. This study demonstrated that proactive
304 collaboration with assay manufacturers would enable laboratories to be prepared for emerging diseases
305 like COVID-19. Epidemiological interventions depend on availability of accurate diagnostic tests and
306 throughput capacity of such system during large outbreaks like *SARS-CoV-2*. It is also important to have a
307 well-organized plan to report the test results to public health officials to initiate counter measures to
308 control the infections. It is also imperative to build a diagnostic algorithm to include testing for other
309 seasonal respiratory viruses, especially most common viruses like *Influenza* and *RSV*, which may require
310 medical attention.

311 **Acknowledgment:** Authors would like to thank Jeffry Hunt for help with data extraction and Courtney
312 Shaver for help with statistics.

313

314

315

316

317

318

319

320

321

322

323 **Reference**

- 324 1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for
325 Global Health Governance. *JAMA*. 2020;323(8):709-710. doi:10.1001/jama.2020.1097
- 326 2. Coronavirus. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed March
327 30, 2020.
- 328 3. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease
329 2019 in Wuhan, China. *Clin Infect Dis Off Publ Infect Dis Soc Am*. March 2020.
330 doi:10.1093/cid/ciaa272
- 331 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with
332 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet Lond Engl*.
333 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
- 334 5. [https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-
authorizations#covid19ivd](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-
335 authorizations#covid19ivd).
- 336 6. Tang Y-W, Gonsalves S, Sun JY, et al. Clinical Evaluation of the Luminex NxTAG Respiratory
337 Pathogen Panel. *J Clin Microbiol*. 2016;54(7):1912-1914. doi:10.1128/JCM.00482-16
- 338 7. Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. *Int J Occup Environ Med*.
339 2020;11(2):65-71. doi:10.15171/ijoem.2020.1921
- 340 8. Amrane S, Tissot-Dupont H, Doudier B, et al. Rapid viral diagnosis and ambulatory management of
341 suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France,
342 - January 31st to March 1st, 2020: A respiratory virus snapshot. *Travel Med Infect Dis*. March
343 2020:101632. doi:10.1016/j.tmaid.2020.101632
- 344 9. Romette JL, Prat CM, Gould EA, et al. The European Virus Archive goes global: A growing resource
345 for research. *Antiviral Res*. 2018;158:127-134. doi:10.1016/j.antiviral.2018.07.017
- 346 10. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-
347 time RT-PCR. *Eurosurveillance*. 2020;25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045
- 348 11. Chu DKW, Pan Y, Cheng SMS, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV)
349 Causing an Outbreak of Pneumonia. *Clin Chem*. January 2020. doi:10.1093/clinchem/hvaa029
- 350 12. K K, A K, Y F. COVID-19: Active measures to support community-dwelling older adults. *Travel*
351 *Med Infect Dis*. March 2020:101638. doi:10.1016/j.tmaid.2020.101638
- 352 13. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and
353 Other Respiratory Pathogens. *JAMA*. April 2020. doi:10.1001/jama.2020.6266
- 354 14. Cauchemez S, Ferguson NM, Wachtel C, et al. Closure of schools during an influenza pandemic.
355 *Lancet Infect Dis*. 2009;9(8):473-481. doi:10.1016/S1473-3099(09)70176-8
- 356 15. Adalja AA, Toner E, Inglesby TV. Priorities for the US Health Community Responding to COVID-
357 19. *JAMA*. March 2020. doi:10.1001/jama.2020.3413

358

359 **Figure legends**

360 Fig 1. Baylor Scott and White Memorial hospital initiated testing on March 11, 2020 following an
361 Emergency Use Authorization submission to FDA. The data shown represents more than 3500 tests were
362 performed between March 11, 2020 and March 23, 2020 for the two different regions of Texas State
363 (Central and North).

364

365 Fig 2. Ambulatory patients were prescreened through a set of COVID-19 questionnaire delivered through
366 various channels including BSWH web portal and BSWH App and/or through phone a call to be eligible
367 for testing. Data shown are number of positive patients per day in ambulatory setting.

368

369 Fig 3. Data shown are daily positives from March 11, 2020 to March 23, 2020. Nasopharyngeal
370 specimens were collected from patients presented in the emergency department and/or admitted and were
371 tested on Luminex Aries, a true random access instrument for a faster turn-around time.

372

373 Fig 4. Data shown represent positivity rate among various age groups, also shown are number of tests
374 performed and positive results for each group.

375

376 Fig 5. Epidemiological data reporting to specific public health departments. Patient demographics were
377 extracted from the laboratory information system and segregated number of positive tests for specific
378 counties within central and north Texas regions.

379

380 Fig 6. Decline in seasonal influenza cases. Following the enactment of epidemiological interventions by
381 the state of Texas, large gatherings were banned and public practicing social distancing may have led to
382 the decrease in the number of Influenza positive cases. Data shown are from March 2019 and March 2020
383 for percent positive test results for each virus target. A *Chi*-square test was used to assess the association
384 between the rate of infection for each virus between 2019 and 2020. Statistical significance was set at *p*-
385 *value*<0.05.

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401 Table I. Demographic, comorbidity, symptoms, other social and past medical history of BSWH inpatient
 402 population

Baseline characteristics (total n=14)		
Demographics		
Gender %(n)	Male 29% (4)	Female 71% (10)
Age (years)	Mean 51.6	Range 20-81
BMI	Mean 32, Median 28	Range 22-63
Comorbid conditions		
Type 2 Diabetes Mellitus		28% (4)
Asthma %(n)		36% (5)
COPD %(n)		21% (3)
CHF %(n)		14% (2)
HTN %(n)		50% (7)
Medications		
ACE inhibitor %(n)		28% (4)
Angiotensin receptor blocker %(n)		7% (1)
Social history		
Tobacco %(n)	History of use 57% (8)	Current use 21% (3)
Vaping %(n)	7% (1)	
Marijuana %(n)	7% (1)	
Subjective symptoms		
Symptom time prior (days)	Mean 4, Median 3	Range 1-21
Fever/Chills %(n)		79% (11)
Headache %(n)		36% (5)
Rhinorrhea %(n)		28% (4)
Cough %(n)		79% (11)
Otalgia/pressure %(n)		21% (3)
Odynophagia %(n)		7% (1)
Mild dyspnea %(n)		64% (9)
Severe dyspnea %(n)		21% (3)
Diarrhea %(n)		7% (1)
Clinical characteristics		
Abnormal Chest x-ray %(n)		50% (7)
Peripheral pulse oximetry <94% %(n)		28% (4)
Lymphopenia %(n)		21% (3)
Temperature 38°C/100.4° F %(n)		50% (7)

403

Fig 1. Number of SARS-CoV-2 tests performed at Baylor Scott & White Medical Center




Fig 2. Number of positive cases in ambulatory clinics




Fig 3. Number of positive cases in emergency department/hospitalized patients




Fig 4. Positive test distribution in the specific age group




Fig 5. Number of confirmed cases per specific counties in north and central Texas




Fig 6. COVID-19 impact on other seasonal respiratory viruses

